Press Releases

FOR IMMEDIATE RELEASE  Contact:   Christina Cherel at ccherel@nwhn.org or (202) 682-2640   WASHINGTON, D.C. – The National Women’s Health Network (the Network) is profoundly disappointed with the U.S. Food and Drug Administration’s (FDA) decision to approve flibanserin, a proposed treatment for female sexual dysfunction, despite inadequate proof of effectiveness and questionable assurances of the drug’s safety. The FDA’s recommendation for ...

FOR IMMEDIATE RELEASE  Contact: Media@nwhn.org or Cindy Pearson at 301-938-0356   (Washington, D.C.) The National Women’s Health Network (“the Network”) boldly stands with All* Above All and our pro-choice Congressional champions to restore and sustain abortion coverage for low-income women. We celebrate the introduction of the Equal Access to Abortion Coverage in Health Insurance (EACH) Woman Act as ...

FOR IMMEDIATE RELEASE  Contact: Cindy Pearson at 301-938-0356 or Coco Jervis at 202-407-0788   The National Women’s Health Network (“the Network”) urges the FDA to oppose the approval of Sprout Pharmaceutical’s female sexual dysfunction drug flibanserin. The Network has come to this position after careful consideration of newly disclosed research and thorough evaluation of the drug’s extensive and ...

FOR IMMEDIATE RELEASE Contact:  Coco Jervis 202.407.0788   Advocates from the National Women’s Health Network are out in force this week at the FDA and on the Hill urging FDA officials to approve of a proposed Generic Drug Labeling Rule. This rule would give women access to better and more accurate information about the risks and benefits of ...